Pacific Biosciences of California, Inc. develops, manufactures, and markets an integrated platform for genetic analysis. The company engages in developing a single molecule, real-time, (SMRT) technology for the detection of biological processes. Its SMRT technology enables to study the synthesis, composition, structure, and regulation of DNA, as well as to record individual biochemical events as they occur. It primarily focuses on the deoxyribonucleic acid sequencing market. The company's product includes the PacBio RS high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Its PacBio RS high resolution genetic analyzer consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits to prepare and sequence DNA samples. The company's customers include genome centers, genomics service providers, and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. markets its products through a direct sales force in North America and Europe, as well as through distributors in Asia. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Key stats and ratios
|
| Net profit margin | -338.48% | -363.56% |
| Operating margin | -330.64% | -363.08% |
| EBITD margin | - | -337.49% |
| Return on average assets | -59.92% | -54.29% |
| Return on average equity | -79.15% | -62.80% |
| Employees | 342 | - |
|
|
|
Address
1380 Willow Rd.
MENLO PARK, CA 94025
United States
No comments:
Post a Comment